Welcome to our dedicated page for VivoSim Labs SEC filings (Ticker: VIVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The VivoSim Labs, Inc. (VIVS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq‑listed pharmaceutical and biotechnology services company, VivoSim Labs uses these filings to report on corporate governance, executive compensation, auditor ratification, board elections and other matters relevant to stockholders.
Core documents include annual proxy statements on Schedule 14A, where the company outlines items such as the election of directors, the ratification of its independent registered public accounting firm, advisory votes on executive compensation and the frequency of say‑on‑pay votes. These materials also summarize aspects of VivoSim Labs’ governance framework, including board composition, independence, committee structure and compensation practices.
Current reports on Form 8‑K provide timely disclosure of specific events, such as the appointment of key executives. For example, VivoSim Labs has filed an 8‑K describing the appointment of a Chief Commercial Officer, including information about the role, background and related compensatory arrangements. Another 8‑K reports the results of the company’s annual meeting of stockholders, detailing vote counts for director elections, auditor ratification and advisory proposals.
On Stock Titan, these filings are supplemented with AI-powered summaries that explain the significance of each document in clear language. Users can quickly understand the outcomes of stockholder votes, changes in leadership roles and the structure of executive compensation without reading every page of the underlying filing. The page also surfaces Forms 10‑K and 10‑Q when available, along with Forms 4 and other ownership reports, enabling investors to review periodic reporting and insider transaction disclosures with AI‑generated highlights and context.
VivoSim Labs, Inc. is registering up to $4,000,000 of securities in a best efforts public offering of up to 2,366,862 shares of common stock (or pre-funded warrants in lieu of common stock), sold together with 3,550,293 common warrants. The common warrants are exercisable at 120% of the combined offering price, include anti-dilution and a cashless exercise feature that can significantly increase the number of shares issued. The deal is split into an Initial Tranche of up to $3,000,000 and a conditional Second Tranche of up to $1,000,000. As of December 31, 2025, VivoSim had 2,607,962 shares outstanding, rising to about 4,974,824 shares if the offering is fully subscribed, excluding warrant exercises. The company expects net proceeds of roughly $3.4 million at the assumed $1.69 price, to fund working capital, R&D, regulatory, IP and general corporate purposes. Management warns of substantial dilution risk from the warrants’ cashless exercise mechanics and states that current cash, without this capital raise, is not sufficient to fund operations beyond mid-2026, with a going-concern explanatory paragraph in the latest audit report.
VivoSim Labs, Inc. is registering up to 2,366,862 shares of common stock, or pre-funded warrants in lieu of those shares, in a best efforts public offering bundled with common warrants. The structure also registers the underlying shares for the pre-funded, common and placement agent warrants.
The company plans to raise up to $4,000,000 in common stock or pre-funded warrants and up to $15,000,000 in common shares underlying warrants, sold at an assumed combined price of $1.69. The deal is split into a $3,000,000 Initial Tranche and a conditional $1,000,000 Second Tranche.
VivoSim provides 3D human tissue-based toxicology services and is advancing an IBD drug program after selling its FXR314 program for $10.0 million. It reports an accumulated deficit of $350.2 million and warns of substantial doubt about its ability to continue as a going concern without new capital; net proceeds of about $3.4 million are earmarked for working capital and general corporate purposes.
VivoSim Labs, Inc. reported very modest revenue and continued losses for the quarter ended December 31, 2025 while disclosing substantial doubt about its ability to continue as a going concern.
Quarterly revenue was about $26,000, all from royalty income, and the company posted a net loss of roughly $2.7 million, narrower than the prior year’s loss. For the first nine months of fiscal 2026, the net loss reached about $8.1 million.
Cash and cash equivalents fell to roughly $4.3 million at December 31, 2025 from $11.3 million at March 31, 2025, driven by about $8.6 million of negative operating cash flow, partially offset by $1.8 million of at-the-market equity proceeds and prior FXR program sale proceeds. Management states that, under its current operating plan, additional capital will be needed and current conditions raise substantial doubt about its ability to fund operations for at least one year after issuance of these financial statements.
VivoSim Labs director Douglas Jay Cohen received 15,000 shares of common stock in the form of restricted stock units on January 27, 2026 at a price of $0 per share. These units vest on the earlier of January 27, 2027 or the next annual stockholder meeting, with possible acceleration upon a change of control.
After this grant, Cohen directly beneficially owns 20,732 shares of common stock, and 83 shares are held indirectly by his son and 83 shares are held indirectly by his daughter. All share amounts reflect a 1-for-12 reverse stock split effective March 20, 2025.
VivoSim Labs executive chairman Murphy Keith received 15,000 shares of common stock as a stock-based award. The grant took place on January 27, 2026 at a price of $0.00 per share and is represented by restricted stock units.
The restricted stock units vest on the earlier of January 27, 2027 or the date of the next annual meeting of stockholders, with possible acceleration if there is a change of control. After this grant, Keith beneficially owned 26,053 shares of VivoSim Labs common stock, with all reported share amounts reflecting a prior 1-for-12 reverse stock split effective March 20, 2025.
VivoSim Labs, Inc. director Milhous Alison Tjosvold was granted 15,000 shares of common stock on January 27, 2026. The award is represented by restricted stock units that will vest on the earlier of January 27, 2027, or the next annual stockholder meeting, with potential acceleration upon a change of control. After this grant, the director beneficially owns 19,899 shares of common stock. All share amounts already reflect a 1-for-12 reverse stock split that became effective on March 20, 2025.
VivoSim Labs director David Gobel received 15,000 shares of common stock in the form of restricted stock units at no cost on January 27, 2026. These units will vest on the earlier of January 27, 2027 or the company’s next annual stockholder meeting, with potential acceleration if there is a change of control. After this award, Gobel beneficially owns 15,000 shares directly.
VivoSim Labs director Adam K. Stern received 15,000 shares of common stock on a restricted stock unit basis on January 27, 2026 at a price of $0.00 per share. These units vest on the earlier of January 27, 2027 or the next annual stockholder meeting, with possible acceleration upon a change of control. Following this award, Stern beneficially owns 19,899 shares directly. All share figures reflect a 1-for-12 reverse stock split of VivoSim Labs common stock that became effective on March 20, 2025.
VivoSim Labs, Inc. reported the results of its 2025 Annual Meeting of Stockholders. Of the 2,607,962 shares of common stock outstanding as of the October 17, 2025 record date, 972,769 shares, or 37.29%, were represented, satisfying the quorum requirement.
Stockholders elected Douglas Jay Cohen and David Gobel as Class II directors to serve until the 2028 annual meeting. They ratified Rosenberg Rich Baker Berman P.A. as independent registered public accounting firm for the fiscal year ending March 31, 2026, with 97.91% of votes cast in favor. On an advisory basis, stockholders approved executive compensation with 89.97% support and chose “one year” as the preferred frequency for future advisory votes on executive pay, with 97.17% of votes cast supporting annual votes. The company will hold these advisory votes on an annual basis going forward.
VivoSim Labs, Inc. (VIVS) filed a Form 4 reporting a director’s change in ownership. On 11/17/2025, the director reported a transaction involving 3,266 shares of common stock at $2.2351 per share, and reported 0 shares beneficially owned following the transaction, held directly.
The company notes that, effective March 20, 2025, it completed a 1-for-12 reverse stock split of its common stock, and all share amounts in this filing already reflect that split.